Absci (NASDAQ:ABSI) and leading researchers at the California Institute of Technology received a grant from the Bill & Melinda Gates Foundation for a joint effort to discover affordable HIV therapeutic vaccinations...
As CEO and founder of Absci (NASDAQ:ABSI), a drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, Sean McClain has come a long way in the...
Absci (NASDAQ:ABSI), which uses deep learning AI and synthetic biology to expand the therapeutic potential of proteins, entered a research collaboration with Merck (known as MSD outside the U.S. and Canada), using...